title: Improved treatment and survival for lung cancer patients in South-East Scotland.
abstract: BACKGROUND
  Lung cancer survival in Scotland has historically been poor but many changes to the lung cancer services have been introduced and this study was conducted to investigate the impact of these changes on treatment and survival.
  
  
  METHODS
  Data obtained from the Scottish Cancer Registry, South-East Scotland Cancer Network audit and Edinburgh Cancer Centre database were used to conduct a comparison of the management and outcomes of lung cancer patients from South-East Scotland diagnosed in 1995 and in 2002.
  
  
  RESULTS
  Data on 971 patients diagnosed in 2002 and 927 in 1995 were analyzed and demonstrated that though the use of treatment overall had not changed (62% in 2002 versus 63% in 1995) the use of potentially curative radiotherapy (15 versus 5% chi p < 0.001) and chemotherapy for non-small cell lung cancer (18 versus 7% chi p < 0.001) had increased, but not resection rates (11 versus 10%). The use of palliative radiotherapy declined (38% versus 31% chi p < 0.001). Patients diagnosed in 2002 had an adjusted hazard of death of 0.7 (95% confidence interval, 0.6-0.8) compared with 1995, with median survival from date of diagnosis of 5.2 versus 4.1 month and 2 year overall survival 15 versus 11% (log rank p = 0.004). Localized disease and younger age were also associated with a reduced hazard of death.
  
  
  CONCLUSIONS
  Patients diagnosed with lung cancer in Scotland in 2002 had a reduced hazard of death and improved survival compared with 1995. It is hypothesized that this was due in part to improvements in service organization and increased use of treatments likely to increase survival.
authors.affiliation: Edinburgh Cancer Centre, Western General Hospital, Edinburgh. serridge@staffmail.ed.ac.uk
authors.forename: Sara C
authors.initials: SC
authors.lastname: Erridge
authors.forename: Brian
authors.initials: B
authors.lastname: Murray
authors.forename: Allan
authors.initials: A
authors.lastname: Price
authors.forename: Janet
authors.initials: J
authors.lastname: Ironside
authors.forename: Felicity
authors.initials: F
authors.lastname: Little
authors.forename: Melanie
authors.initials: M
authors.lastname: Mackean
authors.forename: William
authors.initials: W
authors.lastname: Walker
authors.forename: David H
authors.initials: DH
authors.lastname: Brewster
authors.forename: Roger
authors.initials: R
authors.lastname: Black
authors.forename: Ron J
authors.initials: RJ
authors.lastname: Fergusson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology / Q000628:therapy*; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D016015:Logistic Models; D008175:Lung Neoplasms / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012042:Registries; D012606:Scotland / Q000453:epidemiology; D016019:Survival Analysis